학술논문
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Document Type
Article
Author
Source
Pediatric Blood & Cancer; Aug2022, Vol. 69 Issue 8, p1-7, 7p
Subject
Language
ISSN
15455009